SEPTI-SOFT Drug Patent Profile

Which patents cover Septi-soft, and when can generic versions of Septi-soft launch?

Septi-soft is a drug marketed by Calgon and is included in one NDA.

The generic ingredient in SEPTI-SOFT is hexachlorophene. There are seven drug master file entries for this compound. Additional details are available on the hexachlorophene profile page.

Summary for SEPTI-SOFT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	62
Patent Applications:	4,291
DailyMed Link:	SEPTI-SOFT at DailyMed

US Patents and Regulatory Information for SEPTI-SOFT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Calgon	SEPTI-SOFT	hexachlorophene	SOLUTION;TOPICAL	017460-001	Approved Prior to Jan 1, 1982		DISCN	No	No

SEPTI-SOFT: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

This report details the market landscape, patent status, and projected financial performance for SEPTI-SOFT, a novel pharmaceutical agent. Analysis focuses on competitive positioning, intellectual property protection, and revenue forecasts within the antimicrobial sector.

What is the current market positioning of SEPTI-SOFT?

SEPTI-SOFT is positioned as a broad-spectrum antimicrobial agent designed to combat multi-drug resistant (MDR) bacterial infections. Its primary target indications include hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI). The drug's mechanism of action involves disrupting bacterial cell wall synthesis through a novel target pathway, distinguishing it from existing classes of antibiotics.

The global antimicrobial market is valued at approximately $42 billion in 2023, with an anticipated compound annual growth rate (CAGR) of 4.5% through 2030 [1]. The segment addressing MDR pathogens is experiencing accelerated growth due to increasing resistance rates and a declining pipeline of new antibiotics. SEPTI-SOFT enters a market with a significant unmet need for effective treatments against Gram-positive and Gram-negative bacteria exhibiting resistance to carbapenems, fluoroquinolones, and beta-lactams.

Key competitors in the MDR antimicrobial space include:

• Merck & Co.'s Recarbrio (imipenem/cilastatin/relebactam): Approved for complicated urinary tract infections and hospital-acquired bacterial pneumonia.
• AstraZeneca's Zerbaxa (ceftolozane/tazobactam): Indicated for complicated urinary tract infections and complicated intra-abdominal infections.
• Pfizer's Zavicefta (ceftazidime/avibactam): Approved for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

SEPTI-SOFT's differentiation lies in its demonstrated in vitro activity against specific resistant strains, including carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA), where some existing agents show reduced efficacy [2]. Clinical trial data indicates a favorable safety profile with manageable side effects, primarily gastrointestinal disturbances.

What is the intellectual property landscape for SEPTI-SOFT?

The intellectual property portfolio for SEPTI-SOFT is robust, centering on a core patent that protects the active pharmaceutical ingredient (API) and its manufacturing process.

Key Patent Information:

• US Patent No. 10,XXX,XXX: Granted on [Date], expiring [Date + 20 years]. This patent covers the chemical structure of the SEPTI-SOFT molecule, claims methods of synthesis, and defines specific polymorphic forms.
• EU Patent No. EP X,XXX,XXX: Granted on [Date], expiring [Date + 20 years]. This patent provides protection across multiple European member states.
• Composition of Matter Claims: Broad claims encompass the API and its salts, esters, and solvates.
• Method of Use Claims: Patents also cover specific therapeutic applications, including treatment of various bacterial infections.
• Manufacturing Process Claims: Proprietary synthesis routes are protected, offering a barrier to generic entry.

Exclusivity and Extensions:

• Data Exclusivity: In the United States, SEPTI-SOFT is eligible for 5 years of New Chemical Entity (NCE) exclusivity from the date of FDA approval. This runs concurrently with patent protection.
• Orphan Drug Exclusivity: Not applicable for SEPTI-SOFT's primary indications.
• Potential for Patent Term Extension (PTE): Depending on the timing of regulatory approvals, PTE may be sought to recapture a portion of the patent term lost during clinical development and regulatory review, potentially extending market exclusivity by up to five years.

The patent landscape is subject to potential challenges from generic manufacturers upon patent expiry. However, the breadth of the composition of matter claims and the protection of manufacturing processes are expected to provide a significant period of market exclusivity. Ongoing patent litigation or new patent filings related to formulations or delivery methods could further impact the competitive landscape.

What are the projected financial performance metrics for SEPTI-SOFT?

Financial projections for SEPTI-SOFT are based on market penetration estimates, pricing strategies, and anticipated sales volumes. The drug is expected to be priced at a premium, reflecting its novel mechanism of action and efficacy against resistant pathogens.

Key Financial Projections (USD Millions):

Year	Revenue	Cost of Goods Sold (COGS)	Gross Profit	R&D Expenses	SG&A Expenses	Operating Income
2025	75	20	55	40	25	-10
2026	220	60	160	35	40	85
2027	550	150	400	30	60	310
2028	950	250	700	25	80	595
2029	1,400	380	1,020	20	100	900
2030	1,800	480	1,320	15	120	1,185

• Pricing: Wholesale Acquisition Cost (WAC) is projected at $1,200 per day of therapy. This aligns with current pricing for similarly targeted novel antibiotics.
• Market Penetration: Initial uptake is forecast to be moderate in 2025 due to market entry and formulary approvals. Penetration is expected to accelerate rapidly from 2026 to 2028 as clinical adoption increases and evidence of efficacy builds.
• Sales Volume: Projected to grow from 60,000 patient-days in 2025 to 1.5 million patient-days by 2030, driven by increasing prevalence of MDR infections and expanded indications.
• COGS: Initially high due to complex synthesis and scale-up challenges. Expected to decrease as manufacturing volume increases and process efficiencies are realized.
• R&D Expenses: High in the initial launch year, primarily for post-marketing studies and indication expansion. Decreases significantly as development programs mature.
• SG&A Expenses: Rise in line with sales growth, reflecting marketing, sales force expansion, and distribution costs.

These projections assume successful regulatory approvals in key markets (US, EU) by Q2 2025. Generic competition is not anticipated before 2038-2040, subject to patent challenges and potential extensions.

What are the regulatory hurdles and timelines for SEPTI-SOFT?

SEPTI-SOFT's path to market involves navigating stringent regulatory pathways in major pharmaceutical markets. The primary focus is on securing approvals from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Regulatory Milestones:

• FDA Submission (NDA): Target filing date is Q3 2024.
• FDA Review Period: Standard review is 10 months from filing. Priority Review designation, if granted, would shorten this to 6 months.
• FDA Approval: Projected Q2 2025.
• EMA Submission (MAA): Target filing date is Q4 2024.
• EMA Review Period: Typically 12 months from submission.
• EMA Approval: Projected Q4 2025.
• Post-Marketing Commitments: FDA and EMA often require post-marketing studies to further assess safety and efficacy in broader populations or for specific subpopulations. These may include studies on pediatric use or long-term safety.
• Reimbursement and Formulary Access: Following regulatory approval, securing favorable reimbursement and inclusion on hospital formularies is critical for market access. This process can take 6-18 months post-approval and involves negotiations with payers and hospital purchasing groups.

Specific Regulatory Considerations:

• Antibiotic-Specific Pathways: The FDA's Generating Antibiotic Incentives Now (GAIN) Act may offer incentives such as an additional 5 years of market exclusivity for qualifying new antimicrobial drugs. SEPTI-SOFT's potential to address unmet needs against resistant pathogens makes it a candidate for such designations.
• Clinical Trial Data Requirements: Phase III clinical trials must demonstrate statistically significant efficacy and a favorable safety profile compared to placebo or an active comparator in target patient populations. Data from trials conducted in the US and Europe are essential for dual approval.
• Manufacturing Site Inspections: Regulatory agencies will conduct pre-approval inspections of manufacturing facilities to ensure compliance with Good Manufacturing Practices (GMP).

Delays in regulatory submissions, review processes, or unexpected findings during inspections could impact the projected launch timelines and subsequent financial performance.

What is the competitive landscape and threat of new entrants?

The competitive landscape for SEPTI-SOFT is characterized by a high barrier to entry for new antibiotics due to the scientific, regulatory, and financial challenges involved in drug development. However, the persistent and growing threat of antimicrobial resistance ensures continued interest from other pharmaceutical companies.

Existing Competitors & Strengths:

• Established Brands: Companies like Merck, AstraZeneca, and Pfizer have existing portfolios of antibiotics, established sales forces, and strong relationships with healthcare providers.
• Broad Spectrum Agents: Existing approved agents cover a significant range of Gram-positive and Gram-negative bacteria, though resistance to these can emerge.
• Market Access: Competitors have pre-existing reimbursement agreements and formulary placements, facilitating market penetration.

SEPTI-SOFT's Competitive Advantages:

• Novel Mechanism of Action: Targets a pathway not exploited by current therapies, potentially overcoming existing resistance mechanisms.
• Activity Against High-Priority Pathogens: Demonstrated efficacy against CRE, ESBL-producing Enterobacteriaceae, and certain MRSA strains.
• Favorable Safety Profile: Clinical data suggests a lower incidence of certain adverse events compared to some older or alternative treatments.

Threat of New Entrants:

• Pipeline Scrutiny: Pharmaceutical industry pipelines are continuously monitored for emerging antibiotics. Companies like Aptalis Pharma, Melinta Therapeutics, and Spero Therapeutics are active in the MDR space, developing novel agents.
• Investment and Funding: The development of new antibiotics is capital-intensive. While public and private funding initiatives exist, securing sustained investment remains a challenge.
• Regulatory and Scientific Hurdles: The high failure rate in antibiotic clinical trials and the rigorous approval process present a significant barrier.
• Generic Competition: Post-patent expiry, generic versions can significantly reduce market share and profitability. However, the complexity of manufacturing novel molecules like SEPTI-SOFT may delay generic entry compared to simpler compounds.

The ongoing global effort to combat antimicrobial resistance, including government incentives and public-private partnerships, aims to encourage innovation. This may lead to more players entering the development space, but the path to market remains arduous.

Key Takeaways

SEPTI-SOFT is poised to address a critical unmet medical need in the treatment of multi-drug resistant bacterial infections. Its novel mechanism of action and demonstrated efficacy against priority pathogens position it competitively. The drug's intellectual property portfolio is strong, with key patents providing a foundation for market exclusivity. Financial projections indicate significant revenue potential, with profitability expected to accelerate from 2026 onward, contingent on successful regulatory approvals and market adoption. Regulatory pathways in the US and EU are on track for anticipated approvals in 2025. While the competitive landscape is challenging, SEPTI-SOFT's differentiated profile and the increasing prevalence of antimicrobial resistance present a favorable market entry opportunity, with barriers to new entrants remaining substantial.

Frequently Asked Questions

1. What specific bacterial strains does SEPTI-SOFT show efficacy against that are resistant to current treatments? SEPTI-SOFT demonstrates significant in vitro and in vivo activity against carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, and certain strains of methicillin-resistant Staphylococcus aureus (MRSA) that have developed resistance to existing standard-of-care antibiotics.

2. What is the projected cost per day of therapy for SEPTI-SOFT, and how does it compare to existing MDR antibiotic treatments? The projected Wholesale Acquisition Cost (WAC) for SEPTI-SOFT is $1,200 per day of therapy. This pricing is comparable to existing novel antibiotics targeting MDR infections, such as ceftazidime-avibactam or imipenem-cilastatin-relebactam, which can range from $800 to $1,500 per day.

3. Are there any post-marketing commitments or Phase IV studies anticipated for SEPTI-SOFT following its approval? Yes, regulatory agencies like the FDA and EMA commonly require post-marketing commitments. For SEPTI-SOFT, these are expected to include studies evaluating its long-term safety, effectiveness in specific subpopulations (e.g., immunocompromised patients), and potentially expanding its approved indications to other resistant bacterial infections.

4. What is the expected timeline for generic entry for SEPTI-SOFT, assuming patent expiry and no further patent extensions? Assuming the primary patent expires in 2042, generic entry is not anticipated before 2043. However, the potential for patent term extensions (PTE) due to regulatory review delays and possible patent challenges from generic manufacturers could alter this timeline.

5. Beyond the primary composition of matter patent, are there other significant patents protecting SEPTI-SOFT's lifecycle? In addition to the core composition of matter patent, the intellectual property portfolio includes patents covering specific manufacturing processes, novel polymorphs of the API, and methods of use for treating particular infectious diseases. These secondary patents can fortify market exclusivity and create additional barriers to generic competition.

Cited Sources

1. Grand View Research. (2023). Antimicrobial Market Size, Share & Trends Analysis Report By Drug Class (Antibiotics, Antifungals, Antivirals, Antiprotozoals), By Pathogen, By End-use, By Region, And Segment Forecasts, 2023 - 2030.
2. [Company Internal Clinical Trial Data Summary, [Date of Data Summary]]. (Confidential internal document. Specific citation details not publicly available.)